APACMed 2020: Dynamic China Market Will Heed COVID-19 Lessons For System Improvement In '21
To the watching world, China dealt quickly and firmly with COVID-19. Seen from within, the health care system is still adapting to the pandemic, but the government is taking the longer view.
You may also be interested in...
Only three of 40 qualified international drug firms won in the latest round of China's central bidding process, showing a toughening environment. But some companies are seemingly determined not to lower prices any further.
Chinese monitoring of the spread of COVID-19 locally has reported no new cases of home-grown infection in a single day for the first time since the outbreak began. It indicates control efforts, including the NMPA’s fast-tracking of relevant devices, PPE and IVDs, are having the desired effects.
The barriers for health-care industry entrants into China are lowering, but still not as quickly as many medtech companies would like. New structural health-care delivery plans are instilling more confidence in a market and industry that in the past have been regarded with caution.